#POLB Poolbeg Pharma PLC – POLB 001 to feature in CRS research programme December 8, 2025 – Posted in: Poolbeg Pharma (POLB)

8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the POLB 001 TOPICAL trial is to feature in a groundbreaking cancer immunotherapy-induced cytokine release syndrome (“CRS”) research programme. Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme supported by…

#POLB Poolbeg Pharma PLC – Result of upsized oversubscribed BookBuild Offer May 23, 2025 – Posted in: Poolbeg Pharma (POLB)

Result of upsized and oversubscribed BookBuild Offer · Conditionally raised gross proceeds of £150,000 from the upsized and oversubscribed BookBuild Offer · Total gross proceeds conditionally raised pursuant to the Fundraising therefore increased to £4.865 million · Use of net proceeds from the Fundraising: o Phase 2a clinical trial for POLB 001, targeting prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS) o Oral GLP-1 proof-of-concept clinical trial o Cash runway extended through to 2027 Poolbeg Pharma…

#POLB Poolbeg Pharma PLC – POLB 001 Patent Granted in Korea March 20, 2025 – Posted in: Poolbeg Pharma (POLB)

20 March 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg’s Republic of Korea Immunomodulator II patent application providing protection to POLB 001 for the treatment of severe influenza to December 2038. POLB 001 is a potent and selective p38 MAP…

#POLB Poolbeg Pharma PLC – POLB 001 Patent Granted in United States November 20, 2024 – Posted in: Poolbeg Pharma (POLB)

20 November 2024- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the US Patent Office has notified the Company of its official decision to grant Poolbeg’s US Immunomodulator I patent application. The claims cover POLB 001, and other p38 MAP kinase inhibitors, for the treatment of patients at risk of severe influenza after an…

#POLB Poolbeg Pharma PLC – Further data shows POLB001 potential in cancer CRS January 17, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater than US$1 billion Key highlights – Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model – Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS – Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS –…

#POLB Poolbeg Pharma PLC – POLB001 Data to be Presented at ASH Annual Meeting November 3, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

3 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that an abstract detailing POLB 001’s promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at 65th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, to be held 9-12 December 2023 in San Diego, California. The ASH Annual Meeting and Exposition…

#POLB Poolbeg Pharma PLC – POLB 001 Oncology Programme Update Meeting November 1, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

1 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors and analysts on the POLB 001 Oncology Programme on Monday 6 November 2023 at 2:00pm – 3:30pm GMT via the Investor Meet Company platform. The event will provide an update and greater detail on Poolbeg’s POLB 001 Oncology programme, which is…

#POLB Poolbeg Pharma PLC – POLB 001 to feature in CRS research programme December 8, 2025 – Posted in: Poolbeg Pharma (POLB)

#POLB Poolbeg Pharma PLC – Result of upsized oversubscribed BookBuild Offer May 23, 2025 – Posted in: Poolbeg Pharma (POLB)

#POLB Poolbeg Pharma PLC – POLB 001 Patent Granted in Korea March 20, 2025 – Posted in: Poolbeg Pharma (POLB)

#POLB Poolbeg Pharma PLC – POLB 001 Patent Granted in United States November 20, 2024 – Posted in: Poolbeg Pharma (POLB)

#POLB Poolbeg Pharma PLC – Further data shows POLB001 potential in cancer CRS January 17, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

#POLB Poolbeg Pharma PLC – POLB001 Data to be Presented at ASH Annual Meeting November 3, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

#POLB Poolbeg Pharma PLC – POLB 001 Oncology Programme Update Meeting November 1, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

Address

Contact

Social

LEGAL